🇺🇸 FDA
Pipeline program

Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

INCB 54828-302

Phase 3 small_molecule active

Quick answer

Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung for Cholangiocarcinoma is a Phase 3 program (small_molecule) at Incyte Biosciences Distribution B.V. with 1 ClinicalTrials.gov record(s).

Program details

Company
Incyte Biosciences Distribution B.V.
Indication
Cholangiocarcinoma
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials